Abbott has disclosed a global collaboration with Medtronic to develop a continuous glucose monitoring (CGM) system, leveraging Abbott's advanced FreeStyle Libre technology. Abbott's CGM sensor will be integrated with Medtronic's automated insulin delivery and smart insulin pen systems as part of the collaboration, which serves as a comprehensive diabetes management solution.
The integrated system will enable automatic insulin adjustments to support optimal glucose levels, which will be advantageous to the over 11 million individuals worldwide who are diagnosed with Type 1 and Type 2 diabetes and require multiple daily administrations of rapid-acting insulin. Medtronic will disseminate the CGM sensor that Abbott will devise specifically for use with its devices.
"This partnership pairs two global leaders in glucose sensing technology and insulin delivery," said Jared Watkin, Executive Vice President of Abbott's diabetes care business. This initiative offers patients a broader range of options for managing their condition with confidence. Over 6 million individuals in 60 countries utilize Abbott's FreeStyle Libre portfolio, which is the world's foremost CGM technology. Abbott is a global healthcare leader that is committed to enhancing the quality of life by providing innovative products in the areas of diagnosis, medical devices, nutrition, and branded generic medications.
